Skip to main content
SpringerLink
Log in

Unerwünschte Arzneimittelwirkungen und Wechselwirkungen von AT1-Rezeptorantagonisten

  • Conference paper
Angiotensin II AT1-Rezeptorantagonisten

  • 20 Accesses

Zusammenfassung

Mit der Zulassung der ACE-Hemmer 1981 in der Bundesrepublik Deutschland stand eine antihypertensive Substanzklasse zur Verfügung, die einen Eingriff in das Renin-Angiotensin-System in der Langzeittherapie möglich machte. Es konnte sehr schnell gezeigt werden, daß diese Substanzklasse sich durch eine sehr gute subjektive und objektive Verträglichkeit auszeichnete. Die Häufigkeit unerwünschter Arzneimittelwirkungen war in den damals durchgeführten Studien geringer als mit anderen antihypertensiven Substanzen. Darüber hinaus konnten Studien zur Lebensqualität von Hochdruckpadenten zeigen, daß die Lebensqualität der Patienten nicht beeinträchtigt wird bzw. sich z.T. sogar verbesserte. Zwar war die Quantität von unerwünschten Wirkungen gering, es zeigten sich jedoch bei größerer Anwendung einige zwar sehr seltene, dafür allerdings bedrohliche unerwünschte Wirkungen, wobei insbesondere das angioneurotische Ödem erwähnt werden muß. Als häufigste substanzspezifische unerwünschte Wirkung stellte sich ein trockener Reizhusten heraus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Acker CG, Greenberg A (1995) Angiooedema induced by the angiotensin II blocker Losartan. N Engl J Med 1572

    Google Scholar 

  2. Ahmad S (1995) Losartan and severe migraine. JAMA 16: 1266

    Google Scholar 

  3. Altun B, Arid M, Yasavul U, Turgan C, Caglar S (1997) Role of erythropoiedn in pathogenesis of post transplant erythrocytosis (PTE) and mechanism of losartan’s efficiency [letter; comment], Nephrol Dial Transplant Mar; 12 (3): 626–7

    CAS  Google Scholar 

  4. Andersson OK, Neldam S (1998) The andhypertensive effect and tolerability of candesartan cilexedl, a new generadon angiotensin II antagonist, in comparison with losartan. Blood Press Jan; 7(1): 53–9

    CAS  Google Scholar 

  5. Aronow WS (1998) The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. Drugs Aging Jun; 12 (6): 423–8

    CAS  Google Scholar 

  6. Aurup P, Smith RD (1998) Losartan and renal transplantadon [letter]. Lancet Mar 28; 351 (9107): 990

    CAS  PubMed  Google Scholar 

  7. Barthelmebs M, Grima M, Imbs JL (1995) Pamipril-induced decrease in renal lithium excretion in the rat. Br J Pharmacol 116 (4): 2161–5

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Barthelmebs M, Al Tebacher M, Madonna O, Grima M, Imbs JL (1995) Absence of a losartan interaction with renal lithium excredon in the rat. Br J Pharmacol 116 (4): 2166–9

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Belcher G, Hubner R, George M, Elmfeldt D, Lunde H (1997) Candesartan cilexedl: safety and tolerability in healthy volunteers and padents with hypertension. J Hum Hypertens Sep; 11 Suppl 2: 85–89

    Google Scholar 

  10. Benz J, Oshrain C, Henry D, Avery C, Chiang YT, Gatlin M (1997) Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol Feb; 37 (2): 101–7

    CAS  Google Scholar 

  11. Birck R, Keim V, Fiedler F, van der Woude FJ, Rohmeiss P (1998) Pancreadtis after losartan [letter]. Lancet Apr 18; 351 (9110): 1178

    CAS  PubMed  Google Scholar 

  12. Blanche P, Raynaud E, Kerob D, Galezowski N (1997) Lithium intoxicadon in an elderly patient after combined treatment with losartan [letter]. Eur J Clin Pharmacol 52 (6): 501

    CAS  PubMed  Google Scholar 

  13. Bornkessel B (1995) Angiotension-II-Rezeptor-Antagonisten. Med Wschharm 18, 6: 148–151

    CAS  Google Scholar 

  14. Bosch X (1997) Losartan-induced hepatotoxicity [letter]. JAMA Nov 19; 278 (19): 1572

    Google Scholar 

  15. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, Mullins F (1997) Pharmacokinedcs of valsartan in padents with liver disease. Clin Pharmacol Ther Sep; 62 (3): 272–8

    CAS  Google Scholar 

  16. Burnier M, Hagman M, Nussberger J (1995) Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 25 (part 1): 602–609

    CAS  PubMed  Google Scholar 

  17. Burnier M, Waeber B, Brunner HR (1994) The advantages of angiotensin II antagonism. J Hypertens suppl. 12/2: 7–15

    Google Scholar 

  18. Chow L, De-Gasparo M, Levens N (1995) Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin ATI receptors. Eur J Pharmacol 25, 282 (1–3), 77–86

    CAS  Google Scholar 

  19. Ciba-Geigy Limited, Diovan (Valsartan CGP 48 933). Expert report on the clinical Documentation. Basle, Switzerland 22-Nov-95

    Google Scholar 

  20. Ciba-Geigy Limited, Tolerability, pharmacokinedcs and pharmacodynamic effects of CGP 48 933 in healthy subjects upon repeat daily administration of 200mg during 8 days. Protocol 03 HPH 9111. Basel, Switzerland, 30-Jun-92

    Google Scholar 

  21. Ciba-Geigy Limited, Pharmacokinedcs, disposition and biotransformadon of CGP 48 933 in healthy male volunteers after a single oral dose of 80 mg 14C-radiolabelled preparadon. Human Pharmacokinetics report HPH 9306, Protocol 16, Basle, Switzerland 15-Mar-95

    Google Scholar 

  22. Ciba-Geigy Limited, Multinadonal, randomised, double-blind placebo- and active-controlled, between patient trail to determine the andhypertensive effect and to assess the tolerability of valsartan 80 mg once daily in patients with uncomplicated hypertension treated for eight weeks. Protocol 51, Basel, Switzerland, 31-Oct-95

    Google Scholar 

  23. Ciba-Geigy Limited, Single-centre, randomised, double-blind within padent trail to assess the tolerability and effect on renal funcdon of valsartan 80 mg once daily, in comparsion to placebo, in patients with renovascular arterial hypertension treated for four days. Protocol 25, Basel, Switzerland, 20-Jun-95

    Google Scholar 

  24. Ciba-Geigy Corporadon, Double-blind, randomized, placebo-controlled, parallel design trial of twelve to fourteen weeks duration to determine the effect of food on the antihypertensive response of CPR 48 933 80 mg in padents with mild to moderate essential hypertension. Protocol 17, Summit, USA, 13-Dec-94

    Google Scholar 

  25. Ciba-Geigy Gm, Diovan Angiotensin II-Antagonist Produktmonographie -Diovan- Fachinformation, Wehr

    Google Scholar 

  26. Cifkova R, Peleska J, Hradec J, Rosolova H, Pinterova E, Zeman K, Oddou-Stock P, Thirlwell J, Botteri F (1998) Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens Aug; 12 (8): 563–7

    CAS  Google Scholar 

  27. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska B (1995) Losartan in heart failure: Hemodynamic effects and tolerability. Circulation 91: 691–97

    CAS  PubMed  Google Scholar 

  28. Dahlöf B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY (1995) Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 8 (6); 578–83

    PubMed  Google Scholar 

  29. Dahlöf B, Lindholm LH, Carney S, Pentikainen PJ, Ostergren J (1997) Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group. J Hypertens Nov; 15 (11): 1327–35

    Google Scholar 

  30. De Smet M, Schoors DF, De Meyer G, Verbesselt R, Goldberg MR, Fitzpatrick V, Somers G (1995) Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br J Clin Pharmacol 40 (6): 571–5

    CAS  PubMed Central  PubMed  Google Scholar 

  31. De Zeeuw D, Gansevoort RT, Dullaart RPF, de Jong PE (1995) Angiotensin II antagonism improves the lipoprotein profile in patients wiht nephrotic syndrome. Journal of hypertension 13 (suppl. 1): 53–58

    Google Scholar 

  32. de-Zeeuw D, Remuzzi G, Kirch W (1997) Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens Sep; 11 Suppl 2: 37–42

    Google Scholar 

  33. Dickstein K, Chang P, Willenheimer R, Haunsö S, Remes J, Hall C, Kjekshus J (1995) Comparsion of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 26: 438–45

    CAS  PubMed  Google Scholar 

  34. Di Pasquale P, Bucca V, Scalzo S, Paterna S (1998) Safety, tolerability, and neurohormonal changes of the combination Captopril plus losartan in the early postinfarction period: a pilot study. Cardiovasc Drugs Ther May; 12 (2): 211–6

    Google Scholar 

  35. Ducloux-D, Bresson Vautrin C, Chalopin JM (1996) Effects of angiotensin-receptor antagonists on erythrocytosis after renal transplantation. Nephrol Dial Transpl 11:1668

    CAS  Google Scholar 

  36. Ducloux D, Chalopin JM (1997) Losartan decreases hemoglobin in renal transplant recipients. Transplant Proc Aug; 29 (5): 2402–3

    CAS  Google Scholar 

  37. Ducloux D, Fournier V, Bresson-Vautrin C, Chalopin JM (1998) Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. Transpl Int 11 (4): 312–5

    CAS  PubMed  Google Scholar 

  38. Ducloux D, Fournier V, Bresson-Vautrin C, Chalopin JM (1997) Treatment of posttransplant erythrocytosis with losartan. Transplant Proc Aug; 29 (5): 2407–8

    CAS  Google Scholar 

  39. Ducloux D, Fournier V, Chalopin JM (1997) Postrenal transplant erythrosis: a direct role for angiotensin II [letter]. Clin Nephrol Apr; 47 (4): 277–8

    CAS  Google Scholar 

  40. Ducloux D, Saint-Hillier Y, Chalopin JM (1997) Effect of losartan on haemoglobin concentration in renal transplant recipients — a retrospective analysis. Nephrol Dial Transplant Dec; 12 (12): 2683–6

    CAS  Google Scholar 

  41. Edwards RM, Trizna W, Stack EJ, Weinstock J (1996) Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 276 (1): 125–9

    CAS  PubMed  Google Scholar 

  42. Fachinformation Atacand/Blopress

    Google Scholar 

  43. Fachinformation Karvea

    Google Scholar 

  44. Fachinformation Teveten

    Google Scholar 

  45. Faison EP, Snavely DB, Thiyagarajan B, Nelson ER (1994) The incidence of cough with the angiotensin II receptor antagonist (Ang II RA), losartan, is significantly less than with angotensin converting enzyme (ACE) inhibitors (ACEI) and is similar to that of placebo. Am J Hypertens 7: 34A

    Google Scholar 

  46. Fritschka E, Philipp T (1993) Spektrum und Häufigkeit von klinischen Nebenwirkungen unter Gabe von Angiotensin-Konversionsenzym-Hemmern. In: Bonner, Rahn, ACE-Hemmer Handbuch, Schattauer Verlag 1993, ISBN 3–7945-1409–2

    Google Scholar 

  47. Frye CB, Pettigrew TJ (1998) Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy Jul-Aug; 18 (4): 866–8

    CAS  Google Scholar 

  48. Gansevoort RT, de Zeew D, Shahinfar S, Redfield A, de Jong PE (1994) Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 12 (suppl 2): 37–42

    Google Scholar 

  49. Goldberg AI, Dinlay MC, Sweet CS (1995) Safety and tolerability of losartan potassium an angiotensin II receptor antagonist. Compared with hydrochlorothiazide, atenolol, felodipin ER and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 75: 793–795

    CAS  PubMed  Google Scholar 

  50. Goldberg MR, Bradstreet TE, Milliams EJ, Tanaka WK (1995) Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosteron system in hypertensive patientes. Hypertension 25: 37–46

    CAS  PubMed  Google Scholar 

  51. Gossmann J, Thurmann P, Bachmann T (1996) Mechanism of angiotensin converting enzyme inhibitor- related anemia in renal transplant recipients. Kidney Int 50: 973–78

    CAS  PubMed  Google Scholar 

  52. Gottlieb SS, Dickstein K, Fleck E (1993) Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88: 1602–09

    CAS  PubMed  Google Scholar 

  53. Gradman AH, Arcure KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS (1995) A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with Enalapril maleate in patientes with essential hypertension. Hypertension 25: 1345–1350

    CAS  PubMed  Google Scholar 

  54. Griffing GT, Melby JC (1982) Enalapril (MK 421) and the white cell count and haematocrit. Lancet 1: 1361

    CAS  PubMed  Google Scholar 

  55. Hamad K, Nakajima Y, Nirei H, Nakajima C, Nagashima A, Sogabe K, Notsu Y, Ono T (1993) The pharmacological characterization of FK 739, a new angiotensin Il-receptor antagonist. JPN J Pharmacol 63/3: 335–343

    Google Scholar 

  56. Hansson L (1995) The future role of losartan. J Hum Hypertens 9 suppl. 5: 55–8

    Google Scholar 

  57. Hoogkamer JF, Kleinbloesem CH, Ouwerkerk M, Hogemann A, Nokhodian A, Kirch W, Weidekamm E (1998) Pharmacokinedcs and safety of candesartan cilexetil in subjects with normal and impaired liver function. Eur J Clin Pharmacol Jun; 54 (4): 341–5

    CAS  Google Scholar 

  58. Horn S, Holzer H, Horina J (1998) Losartan and renal transplantadon [letter] [see comments]. Lancet Jan 10; 351 (9096): 111

    CAS  Google Scholar 

  59. Hortal L, Fernandez A, Vega N, Rodriguez JC, Losada A, Lorenzo M, Plaza C, Palop L (1998) Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis. Transplant Proc Aug; 30 (5): 2127–8

    CAS  Google Scholar 

  60. Imbs JL, Barthelmebs M, Danion JM, Singer L (1997) Mechanisms of drug interacdons with renal elimination of lithium. Bull Acad Nad Med Apr; 181 (4): 685–95; discussion 695–7

    Google Scholar 

  61. Johnston J (1995) Angiotensin receptor antagonists: focus on Losartan. Lancet 346: 1403–07

    CAS  PubMed  Google Scholar 

  62. Johnston CI, Risvanis J (1997) Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens Dec; 10 (12 Pt 2): 306–310

    Google Scholar 

  63. Jonkman JH, van Lier JJ, van Heiningen PN, Lins R, Sennewald R, Hogemann A (1997) Pharmacokinetic drug interacdon studies with candesartan cilexedl. J Hum Hypertens Sep; 11 Suppl 2: 31–5

    Google Scholar 

  64. Julian BA, Brandey RR Jr, Barker CV, Stopka T, Gaston RS, Curtis JJ, Lee JY, Prchal JT (1998) Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol Jun; 9 (6): 1104–8

    CAS  Google Scholar 

  65. Karlberg BE (1993) Cough and inhibition of the renin-angiotensin system. Journal of Hypertension 11 (suppl. 3): 49–52

    Google Scholar 

  66. Kaukonen KM, Olkkola KT, Neuvonen PJ (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol Feb; 53 (6): 445–9

    CAS  Google Scholar 

  67. Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge R, Jorkasky DK (1997) Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther Oct; 62 (4): 417–25

    CAS  Google Scholar 

  68. Kazierad DJ, Martin DE, Ilson B, Boike S, Zariffa N, Forrest A, Jorkasky DK (1998) Eprosartan does not affect the pharmacodynamics of warfarin. J Clin Pharmacol Jul; 38 (7): 649–53

    CAS  Google Scholar 

  69. Kong AN, Tomasko L, Waldman SA, Osborne B, Deutsch PJ, Goldberg MR, Bjornsson TD (1995) Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 35 (10): 1008–15

    CAS  PubMed  Google Scholar 

  70. Kupin W, Venkat KK, Goggins M, Abouljoud M, Escobar F, Mozes M (1997) Benefit of angiotensin II receptor blockade in the treatment of posttransplant polycythemia in renal transplant recipients. Transplant Proc Feb-Mar; 29 (1–2): 207–8

    CAS  Google Scholar 

  71. Lacourciere Y, Lefebvre J (1995) Moduladon of the renin-angiotensin-aldosterone system and cough. Can J Cardiol 11 suppl. F: 33–39

    Google Scholar 

  72. Lai KN, Lui SF (1993) Renin anderythropoitin. In: Robertson JIS, Nicholis MG (eds)The renin-angiotensin system. London, Gower pp 39.1–39.9

    Google Scholar 

  73. Larochelle P, Flack JM, Marbury TC, Sareli P, Krieger EM, Reeves RA (1997) Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am J Cardiol Dec 15; 80 (12): 1613–5

    CAS  Google Scholar 

  74. Lasek R (1998) „SystemPHOENIX“ (Gemeinsame Datenbasis des Bundesinsdtutes für Arzneimittel und Medizinprodukte und der Arzneimittelkommission der deutschen Ärzteschaft) zur Spontanerfassung unerwünschter Arzneimittelwirkungen 12/1998

    Google Scholar 

  75. Lerch M, Teuscher AU, Beissner P, Schneider M, Shaw SG, Weidmann P (1998) Effects of angiotensin II- receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol Apr; 31 (4): 576–80

    CAS  Google Scholar 

  76. Lo MW, Toh J, Emmert SE, Ritter MA, Furtek CI, Lu H, Colucci WS, Uretsky BF, Rucinska E (1998) Pharmacokinetics of intravenous and oral losartan in patients with heart failure. J Clin Pharmacol Jun; 38 (6): 525–32

    CAS  Google Scholar 

  77. Mallion JM, Bradstreet DC, Makris L, Goldberg AI, Halasz S, Sweet CS, Lim NY, Madonna Land O (1995) Antihypertensive efficacy and tolerability of once daily losartan potassium compared with Captopril in padents with mild to moderate essential hypertension. Journal of Hypertension 13 (suppl 1): 35–41

    Google Scholar 

  78. Man in’t-Veld AJ (1997) Clinical overview of irbesartan: expanding the therapeutic window in hypertension. J Hypertens Suppl Dec; 15 (7): 27–33

    Google Scholar 

  79. Marino MR, Langenbacher K, Ford NF, Uderman HD (1998) Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol Mar; 38 (3): 246–55

    CAS  Google Scholar 

  80. Marino MR, Langenbacher KM, Raymond RH, Ford NF, Lasseter KC (1998) Pharmacokinetics and pharmacodynamics of irbesartan in padents with hepatic cirrhosis. J Clin Pharmacol Apr; 38 (4): 347–56

    CAS  Google Scholar 

  81. Mclnnes GT, O’Kane KP, Jonker J, Roth J (1997) The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens Sep; 11 Suppl 2: 75–80

    Google Scholar 

  82. Mcintyre M, Caffé SE, Michalak RA, Reid JL (1997) Losartan, an orally active angiotensin (ATI) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 74 (2): 181–94

    CAS  PubMed  Google Scholar 

  83. Meiracker van de AH, Admiraal PJ, Jansson JA (1995) Hemodynamic and biochemical effects of the AT, receptor antagonist irbesartan in hypertension. Hypertension 25: 22–29

    PubMed  Google Scholar 

  84. Mimran A, Ruilope L, Kerwin L, Nys M, Owens D, Kassler-Taub K, Osbakken M (1998) A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens Mar; 12 (3): 203–8

    CAS  Google Scholar 

  85. Minghelli G, Seydoux C, Goy JJ, Burnier M (1998) Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantati on Jul 27; 66 (2): 268–71

    CAS  Google Scholar 

  86. Moan A, Risanger T, Eide I (1994) The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hyeprtension. Blood pressure 3: 185–188

    CAS  PubMed  Google Scholar 

  87. MSD, Lorzaar 50 mg. Fachinformation Dezember 1995

    Google Scholar 

  88. Munafo A, Christen Y, Nussberger I, Shum L, Borland RM, Lee, RJ (1992) Drug concentration response relationship in normal volunteers after oral administration of D 753, an angiotensin II receptor antagonist. Clin Pharmacol ther 51:513–521

    CAS  PubMed  Google Scholar 

  89. Nakashima M, Uematsu T, Kosuge K, Kanamaru M (1992) Pilot study of the uricosuric effect of D-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42: 333–335

    CAS  PubMed  Google Scholar 

  90. Navarro JF, Garcia J, Macia M, Mora C, Chahin J, Gallego E, Mendez ML, del Castillo N (1998) Effects of losartan on the treatment of posttransplant erythrocytosis. Clin Nephrol Jun; 49 (6): 370–2

    CAS  Google Scholar 

  91. Nelson EB (1995) Clinical profile of the first angiotensin II (AT-1 Specific) Receptor Antagonist Hypertension: Pathophysiology, Diagnosis and Management, Chapter 14, Raven Press

    Google Scholar 

  92. Oparil S, Guthrie R, Lewin AJ, Marbury T, Reilly K, Triscari J, Witcher JA (1998) An elective-titration study of the comparative effectiveness of two angiotensin Il-receptor blockers, irbesartan and losartan. Irbesar- tan/Losartan Study Investigators. Clin Ther May-Jun; 20 (3): 398–409

    CAS  Google Scholar 

  93. Ostermann M, Goldsmith DJ, Doyle T, Kingswood JC, Sharpstone P (1997) Reversible acute renal failure induced by losartan in a renal transplant recipient. Postgrad Med J Feb; 73 (856): 105–7

    CAS  Google Scholar 

  94. Pit B, Segal R, Martinez FA (1997) Randomised trial of Losartan versus Captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747–51

    Google Scholar 

  95. Pitt B (1995) Importance of angiotensin-converting enzyme inhibitors in myocardial infarction and congestive heart failure: Implications for clinical practice. Cardiology 86/suppl. 1 (41–45)

    PubMed  Google Scholar 

  96. Pitt B, Chang P, Timmermans PB (1995) Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc Drugs Ther 9 (5): 693–700

    CAS  PubMed  Google Scholar 

  97. Pool JL, Guthrie RM, Littlejohn TW 3rd, Raskin P, Shephard AM, Weber MA, Weir MR, Wilson TW, Wright J, Kassler-Taub KB, Reeves RA (1998) Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens Apr; 11 (4 Pt 1): 462–70

    CAS  Google Scholar 

  98. Pouleur HG (1997) Clinical overview of irbesartan: a new angiotensin II receptor antagonist. Am J Hypertens Dec; 10(12Pt 2): 318–324

    Google Scholar 

  99. Ramsey LE, Yeo W (1995) On behalf of the Losartan cough studie group. Double-blind comparsion of Losartan, Lisinopril and Hydrochlorothiazide in hypertensive patients with a previous angiotensin convertign enzyme inhibitor-associated cough. J Hypertens 13 (suppl. 1): 73–76

    Google Scholar 

  100. Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, Cushing DJ, Michelson EL (1998) Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol Oct 15; 82 (8): 961–5

    CAS  Google Scholar 

  101. Riddell JG (1997) Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil. J Hum Hypertens Sep; 11 Suppl 2: 29–30

    Google Scholar 

  102. Rijnsoever van EW, Kwee-Zuiderwijk WJ, Feenstra J (1998) Angioneurotic edema attributed to the use of losartan. Arch Intern Med Oct 12; 158 (18): 2063–5

    Google Scholar 

  103. Roca-Cusachs A, Oigman W, Lepe L, Cifkova R, Karpov YA, Harron DW (1997) A randomized, double- blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily Captopril in mild to moderate essential hypertension. Acta Cardiol 52 (6): 495–506

    CAS  PubMed  Google Scholar 

  104. Schmidt EK, Antonin KH, Flesch G, Racine-Poon A (1998) An interaction study with Cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol Feb; 53 (6): 451–8

    CAS  Google Scholar 

  105. Schoenberger JA (1995) Losartan with hydrochlorothiazide in the treatment of hypertension. J Hypertension 13 (suppl 1): 43–47

    Google Scholar 

  106. Scholze J (1996) Angiotensin-II-Rezeptor-Antagonisten. Klinische Relevanz Internist 37: 636–642

    CAS  Google Scholar 

  107. Scholze J, Stapff M (1998) Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor. Br J Clin Pharmacol Aug; 46 (2): 169–72

    CAS  Google Scholar 

  108. Schwarzbeck A, Wittenmeier KW, Hallfritzsch U (1998) Anaemia in dialysis patients as a side-effect of sartanes [letter; comment]. Lancet Jul 25; 352 (9124): 286

    CAS  Google Scholar 

  109. Sever PS (1997) Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil. J Hypertens Suppl Dec; 15 (6): 9–12

    Google Scholar 

  110. Sever P, Holzgreve H (1997) Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens Sep; 11 Suppl 2: 69–73

    Google Scholar 

  111. Shand BI, Gilchrist NL, Nicholls MG (1995) Effect of losartan on haematology and haemorheology in elderly padents with essential hypertension: a pilot study. J Hum Hypertens 9: 233–235

    CAS  PubMed  Google Scholar 

  112. Sharma PK, Yium JJ (1997) Angioedema associated with angiotensin II receptor antagonist losartan. South Med J May; 90 (5): 552–3

    CAS  Google Scholar 

  113. Sica DA, Lo MW, Shaw WC (1995) The pharmacokinetics of losartan in renal insufficiency. J Hypertens 13 (suppl 1): 49–52

    Google Scholar 

  114. Sica DA, Marino MR, Hammet JL, Ferreira I, Gehr TWB, Ford NF (1997) The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clinical Pharmacology & Therapeutics 62 No 6: 610–18

    CAS  Google Scholar 

  115. Simon TA, Gelarden RT, Freitag SA, Kassler-Taub KB, Davies R (1998) Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol Jul 15; 82 (2): 179–82

    CAS  Google Scholar 

  116. Sioufi A, Marfil F, Jaouen A, Cardot JM, Godbillon J, Ezzet F, Lloyd P (1998) The effect of age on the pharmacokinedcs of valsartan. Biopharm Drug Dispos May; 19 (4): 237–44

    CAS  Google Scholar 

  117. Soffer B A, Wright JT, Pratt JH (1995) Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 26: 112–117

    CAS  PubMed  Google Scholar 

  118. Sorensen AM, Christensen S, Jonassen TE, Andersen D, Petersen JS (1998) Teratogenic effects of ACE- inhibitors and angiotensin II receptor antagonists. Ugeskr Laeger Mar 2; 160 (10): 1460–4

    CAS  Google Scholar 

  119. Stumpe KO, Haworth D, Hoglund C, Kerwin L, Martin A, Simon T, Masson C, Kassler-Taub K, Osbakken M (1998) Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press Jan; 7 (1): 31–7

    CAS  Google Scholar 

  120. Sweet CS, Nelson EB (1993) How well have animal studies with losartan predicted responses in humans? Journal of Hypertension 11 (suppl. 3): 63–67

    Google Scholar 

  121. Tedesco MA, Ratd G, Aquino D, Caccavale A, Acitorio M, Rocereto A, Cosimi R, Coppolino P, larussi D, Iacono A (1998) The effecdveness and tolerability of losartan and effect on left ventricular mass in patients with essendal hypertension. Cardiologia Jan; 43 (1): 53–9

    CAS  Google Scholar 

  122. Tedesco MA, Ratd G, Aquino D, Limongelli G, di Salvo G, Menneila S, Galzerano D, larussi D, Iacono A (1998) Effects of losartan on hypertension and left ventricular mass: a long-term study [see comments]. J Hum Hypertens Aug; 12 (8): 505–10

    CAS  Google Scholar 

  123. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S (1998) Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaboradve Group. Hypertension Feb; 31 (2): 684–91

    CAS  Google Scholar 

  124. Trenkwalder P, Lehtovirta M, Dahl K (1997) Long-term treatment with candesartan cilexedl does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens Sep; 11 Suppl 2: 81–3

    Google Scholar 

  125. Vachharajani NN, Shyu WC, Mantha S, Park JS, Greene DS, Barbhaiya RH (1998) Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J Clin Pharmacol May; 38 (5): 433–6

    CAS  Google Scholar 

  126. Vane J (1995) Trumping the ACE. Lancet 346: 916

    CAS  PubMed  Google Scholar 

  127. Velasquez MT (1996) Angiotensin II receptor blockers. A new class of andhypertensive drugs. Arch Fam Med 5 (6): 351–6

    CAS  PubMed  Google Scholar 

  128. Weber M (1997) Clinical safety and tolerability of losartan. Clin Ther Jul-Aug; 19 (4): 604–16; discussion 603

    CAS  Google Scholar 

  129. Weber MA (1997) Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens Suppl Dec; 15 (6): 31–36

    Google Scholar 

  130. Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson E (1995) Blood pressure effects of the angiotensin II receptor blocker losartan. Arch Intern Med 155 (4): 405–11

    CAS  PubMed  Google Scholar 

  131. Williamson KM, Patterson JH, Mueen RH, Adams KF Jr, Pieper JA (1998) Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther Mar; 63 (3): 316–23

    CAS  Google Scholar 

  132. Wilson TW, Lacourciere Y, Barnes CC (1998) The andhypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group [see comments]. CMAJ Sep 8; 159 (5): 469–76

    CAS  Google Scholar 

Download references

Authors
  1. J. Schrader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Lüders
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für experimentelle und klinische Pharmakologie und Toxikologie, Med. Universität zu Lübeck, Ratzeburger Allee 160, D-23538, Lübeck, Deutschland

    Peter Dominiak

  2. Institut für Pharmakologie, Klinikum der Christian-Albrechts-Universität zu Kiel, Hospitalstraße 4, D-24105, Kiel, Deutschland

    Thomas Unger

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Schrader, J., Lüders, S. (1999). Unerwünschte Arzneimittelwirkungen und Wechselwirkungen von AT1-Rezeptorantagonisten. In: Dominiak, P., Unger, T. (eds) Angiotensin II AT1-Rezeptorantagonisten. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-93705-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93705-7_6

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-93706-4

  • Online ISBN: 978-3-642-93705-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation